UK: Briefing Note For Patent Practitioners: An Analysis Of Arrow Declarations Following Glaxo v Vectura

Last Updated: 15 May 2019
Article by Paul A. Harris

The purpose of this briefing note is to raise awareness of the increasing use of Arrow declarations, following on from the Fujifilm v AbbVie decision, which was handed down on 12th January 2017 in the Court of Appeal. The latest case of Glaxo v Vectura ([2018] EWHC 3414 (Pat)) looks at the approach being taken by the English Patents Court and seeks to learn lessons from this. To this extent, it is hoped that patent prosecutors and litigators alike will find something useful to help in their everyday practices.

Fujifilm v AbbVie - A reminder

In what is probably an extreme case, AbbVie sought to extend the protection of its' blockbuster HUMIRA drug which treated various inflammatory diseases, beyond the SPC expiry date of 15 October 2018. It did so by filing numerous applications in respect of various dosage regimes essentially for the same compound. However, as happened in the UK proceedings, shortly before the Patents Court was due to consider the issue of validity and infringement, AbbVie filed a subsequent divisional application, and subsequently they would either disapprove the text or de-designate the EP(UK), so that the Patents Court never had sight of a granted patent. In one case, they were on the 5th divisional application.

What AbbVie sought to achieve was the uncertainty that FKB's generic product under the original granted patent, might inevitably infringe something in the other patent families and their divisionals, particularly if the dosage regime was different, for example. It was for this reason that FKB sought a declaration that their product, at a specific date (in this case the priority date of the original parent application), was old and obvious even though there was no issue relating to the validity of a granted patent, as required under s.74 PA 1977.

Arnold J. stated he could make such a declaration and granted Fujifilm the relief sought. AbbVie subsequently appealed.

In essence, the Court of Appeal approved the approach in Arrow Generics v Merck & Co [2007] in accepting that it is possible for an English Patents Court to grant such declarations. They therefore dismissed AbbVie's appeal.

Glaxo v Vectura

The facts

This case revolved around two sets of patents (the "Patents") for a method of making particles for use in a pharmaceutical composition, and a method of preparing microparticles for use in pharmaceutical compositions for inhalation. In essence, the first group of patents claimed methods of making "composite active particles" and the second group related to methods of making "microparticles" which exhibited and delayed dissolution. Both groups of patents had in common the use of magnesium stearate to form the composite active particles. All of the patents had a priority date of 30th November 2000, which was not challenged.

On 5th August 2010 Vectura granted Glaxo a licence in respect of a specific patent ("the Staniforth patent") and any patents deriving from it (which the judge referred to as "the Staniforth Patents"). The licence provided for royalties, which GSK paid (a "substantial" amount according to the judge) as well as an additional class of patents referred to as the "Non-Assert Patents", over which GSK had an option to take a licence.

The Staniforth Patents expired on 31st January 2016 and subsequently Glaxo stated it did not require a licence under the Non-Assert Patents.

In July 2016 Vectura brought proceedings against Glaxo in the USA for infringement of the US equivalent to the Non-Assert Patents. The following year, in June 2017, Glaxo brought the present proceedings for invalidity (on the grounds of obviousness and insufficiency), as well as seeking the Arrow declaration. Vectura claimed Glaxo infringed the two group of patents by the sale of dry powder inhalers ("DPIs") containing the active ingredients vilanterol trifenatate ('vilanterol') and/or umeclidinium bromide ('umeclidinium') which are used to treat asthma and chronic obstructive pulmonary disease ("COPD"), and sold under the trade mark ELLIPTA.

In seeking invalidity of the two groups of patents on the ground of obviousness, Glaxo relied on three pieces of prior art: the original Staniforth patent and two further patents (Keller and Musa) both relating to DPI's. Glaxo also sought the Arrow declaration based on all three patents (although this was primarily the Staniforth patent, the Musa patent was the one the judge concentrated on). An interesting point for practitioners to note is that at the time of the trial, in the EPO, one patent had already been upheld by the Opposition Division (following opposition by a third party), two were opposed by Glaxo but the proceedings were ongoing, a fourth had been upheld with amended claims (again following opposition by a third party) but the decision was under appeal, and one patent had yet to be opposed.

Glaxo claimed that the process they followed to manufacture its' ELLIPTA product was an obvious modification of Musa (and also Staniforth and Keller).

In carrying out experiments designed to establish infringement (which also proved key in respect to the finding of non-obviousness) reference was made to the claims of the Patents in which there was a requirement to have an additive material (in this case magnesium stearate) present as a coating on the active substance. None of the experiments or the subsequent analysis and results established that the magnesium stearate coated the active substance. That meant that neither Glaxo's processes nor products infringed the Patents.

The flip side of that coin was the reason why the judge found that the Patents were not obvious in the light of the three cited prior art patents, namely, because following the teaching of the cited patents did not produce a product failing within the claims of Vectura's Patents.

The Court's other findings

In addition to finding there was no infringement, and the non-obvious finding over the cited prior art, the judge also found that all the patents were invalid on the ground of insufficiency.

The Arrow declaration

The crux of Glaxo's case in respect of the Arrow declaration was that while vilanterol and/or umeclidinium were not known to be active pharmaceutical ingredients (APIs) as at the priority date, nevertheless that did not matter because once they were known it was obvious to apply the process for use with a DPI.

As Arnold J considers the law in this area, his reasoning from the case is set out below.

The law

241. An Arrow declaration is, in effect, a declaration that, as of a particular date, a party has a Gillette defence against claims of infringement of later patents. The relevant legal principles have been recently considered in the Fujifilm v AbbVie litigation.

242. The jurisdictional position was summarised by Floyd LJ delivering the judgment of the Court of Appeal (cited above) at [98] as follows:

"... we do not consider that there is any issue of principle which prevents the granting of Arrow declarations in appropriate cases. Drawing the threads together:

(i) A declaration that a product, process or use was old or obvious at a particular date does not necessarily offend against s.74 of the Act.

(ii) Such a declaration may offend against the Act where it is a disguised attack on the validity of a granted patent.

(iii) Such declarations do not offend against the scheme of the EPC or the Act simply because the declaration is sought against the background of pending divisional applications by the counter-party.

(iv) On the other hand the existence of pending applications cannot itself be a sufficient justification for granting a declaration.

(v) Whether such a declaration is justified depends on whether a sufficient case can be made for the exercise of the court's discretion in accordance with established principles."

243. The principles upon which the Court will grant such discretionary relief were subsequently considered by Henry Carr J in Fujifilm Kyowa Kirin Biologics Co Ltd v AbbVie Biotechnology Ltd [2017] EWHC 395 (Pat), [2018] RPC 1 at [365]-[371]. In summary, he held that the Court must consider:

i) justice to the claimant;

ii) justice to the defendant;

iii) whether the declaration will serve a useful purpose. The attainment of commercial certainty in patent cases can constitute a useful purpose. The spin-off value of a judgment in other countries may be such a factor, but a declaration sought solely for the benefit of foreign courts will rarely be justified; and

iv) whether or not there are any other special reasons why the court should or should not grant the declaration.

244. At an earlier stage of this case Vectura applied to strike out GSK's claim for an Arrow declaration. The application was granted by HHJ Hacon sitting as a High Court Judge, but his decision was reversed by the Court of Appeal: Vectura Ltd v Glaxo Group Ltd [2018] EWCA Civ 196. Floyd LJ, with whom Birss J agreed, held:

"25. The jurisdiction to grant an Arrow declaration is ... discretionary. Identification of a relevant application is a necessary but not sufficient condition for an application for such relief. It is necessary to go further and examine whether it would serve a useful purpose. The point being made by paragraphs 98(iv) and 98(v) in Fujifilm is the contrast between a remedy which depends only on the existence of a patent (or application) and one whose availability turns on a critical examination of the purpose which its grant would serve.

30. There is no dispute that the declaration must be formulated with clarity. The facts ultimately declared by the court must be clear, otherwise the declaration will simply give rise to further dispute and defeat the purpose for which it is granted. The declaration [i.e. the declaration sought] must also be clear so that the court can know what technical issues it has to decide. The declaration must therefore identify the combination of features of the products and processes in question on which the assessment of obviousness is to take place.

34. ... It is clear from Arrow and the subsequent cases that there is no requirement that the declaration should identify all the features of the product or process. ..."

In essence, if a manufacturer's process or product is alleged to infringe, provided the manufacturer can establish that what he is doing is no more than what was known or done before, or with an obvious modification, then either there is no infringement or else the patent is invalid as it covers what was already known. This is a Gillette defence (named after the case it was first used in namely Gillette Safety Razor Co v Anglo-American Trading Co Ltd (1913) 30 RPC 465).

Having set out the relevant principles, the judge then applied those to the present facts of the case as he found them. As the judge acknowledged, a finding that Glaxo's products were obtained by an obvious process was important, but by itself not sufficient. The judge needed to consider whether granting such relief would serve a useful purpose, and whether the particular circumstances warranted this.

In considering it was appropriate, the judge pointed out that the undertakings given by Vectura were limited in scope, and that it did not mean that with differently formulated claims an infringement finding might occur. This did depend on a method and analysis being able to establish the coating point, but this could not be ruled out. One has to assume that the differently formulated claims point extended also to the insufficiency finding, otherwise if that was insurmountable there would be no point in making the Arrow declaration. Also, the Patents were found not to be obvious in the light of the prior art. In light of these points, the judge considered it appropriate to make an Arrow declaration in a modified version of one of the two forms sought by Glaxo.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions